A. Kohlmann

A. Kohlmann, S. Ramalingam, J. Vansteenkiste, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.

L. Pasqualucci, L. Farinelli, R. Rabadán, 2011, Blood.

CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Haematologica.

Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.

Torsten Haferlach, Alexander Kohlmann, Wolf-Karsten Hofmann, 2009, Blood.

C003 A molecular classification of leukaemia reveals MDS as a disease continuum with non-leukaemia and AML sub groups

A. Kohlmann, T. Haferlach, W. Hofmann, 2007 .

Classification of AML by DNA-oligonucleotide microarrays.

W. Hiddemann, A. Kohlmann, T. Haferlach, 2006, Methods in molecular medicine.

Identification of Differentially Expressed Genes in Scrapie-Infected Mouse Brains by Using Global Gene Expression Technology

Martin Dugas, Alexander Kohlmann, A. Kohlmann, 2004, Journal of Virology.

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice

A. Kohlmann, B. Claes, G. Clark, 2017, ESMO Open.

pathways that associate with disease progression Subnetwork-based analysis of chronic lymphocytic leukemia identifies

T. Ideker, Han-Yu Chuang, L. Rassenti, 2012 .

Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPα DNA binding via leucine zipper domain interaction

D. Tenen, A. Kohlmann, T. Haferlach, 2003, Oncogene.

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).

S. Ogawa, A. Kohlmann, T. Haferlach, 2012, Blood.

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.

M. Iacono, A. Kohlmann, T. Haferlach, 2013, Blood.

ABL populations by ultra-deep sequencing of the resistant − Unraveling the complexity of tyrosine kinase inhibitor

M. Iacono, A. Kohlmann, T. Haferlach, 2013 .

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

F. Saad, N. Agarwal, A. Kohlmann, 2020, The New England journal of medicine.

Discussion of the applicability of microarrays: profiling of leukemias.

A. Kohlmann, T. Haferlach, C. Haferlach, 2009, Methods in molecular biology.

Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients

J. Hernández-Rivas, A. Kohlmann, T. Haferlach, 2013, Leukemia.

Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

A. Kohlmann, E. Shumilov, L. Trümper, 2018, Critical reviews in oncology/hematology.

The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner

D. Tenen, A. Kohlmann, G. Behre, 2003, Oncogene.

Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome

S. Miyano, F. Thol, A. Ganser, 2014, Nature Communications.

TET2 Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence of TET2 Variations

Marcos González, J. Hernández-Rivas, A. Kohlmann, 2014, BioMed research international.

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

P. Jänne, A. Kohlmann, L. Crinò, 2017, JAMA.

Integration of next-generation sequencing into clinical practice: are we there yet?

Torsten Haferlach, Alexander Kohlmann, Vera Grossmann, 2012, Seminars in oncology.

Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure

C Haferlach, M Dugas, A Kohlmann, 2011, Leukemia.

Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo

A. Kohlmann, L. Klein-Hitpass, S. Schnittger, 2013, Cancer cell.

Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, PloS one.

'Deep insight' into microarray technology

A. Kohlmann, T. Haferlach, S. Schnittger, 2011 .

Gene expression profiling in sarcomas.

A. Kohlmann, T. Haferlach, R. Issels, 2007, Critical reviews in oncology/hematology.

Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Genes, chromosomes & cancer.

SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3

Martin C. Müller, S. Ogawa, A. Kohlmann, 2012, Genes, chromosomes & cancer.

Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies.

A. Kohlmann, T. Haferlach, U. Bacher, 2010, Cancer treatment reviews.

Current status of gene expression profiling in the diagnosis and management of acute leukaemia

A. Kohlmann, T. Haferlach, U. Bacher, 2009, British journal of haematology.

Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies.

A. Kohlmann, T. Haferlach, U. Bacher, 2009, Briefings in functional genomics & proteomics.

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

C Haferlach, H Aburatani, S Miyano, 2013, Leukemia.

Molecular characterization of acute leukemias by use of microarray technology

W. Hiddemann, A. Kohlmann, T. Haferlach, 2003, Genes, chromosomes & cancer.

Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients

W Hiddemann, M Dugas, A Kohlmann, 2004, Leukemia.

Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Haematologica.

TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, British journal of haematology.

Gene expression profiling in MDS and AML: potential and future avenues

A Kohlmann, J Boultwood, M. Morgan, 2011, Leukemia.

Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.

A. Kohlmann, T. Haferlach, S. Schnittger, 2005, Journal of the National Cancer Institute.

Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients.

Anders Krogh, Ole Winther, Frederik Otzen Bagger, 2014, Blood.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Paola Fazi, Marco Vignetti, Hans-Ulrich Klein, 2010, Blood.

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

A. Kohlmann, T. Haferlach, M. Vignetti, 2009, Blood.

Gene expression profiling in acute leukemias: New insights into biology and a global approach to the diagnosis of leukemia using microarray technology

A. Kohlmann, 2005 .

AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes

W. Hiddemann, A. Kohlmann, T. Haferlach, 2005, Genes, chromosomes & cancer.

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Blood Cancer Journal.

Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.

A. Trumpp, A. Kohlmann, S. Raffel, 2014, Cell stem cell.

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Leukemia.

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Leukemia.

The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia

A. Kohlmann, T. Haferlach, B. Falini, 2012, Haematologica.

RUNX1 Mutations Are the Most Frequent Leukemia Associated Mutations in Congenital Neutropenia Patients

D. Steinemann, A. Kohlmann, S. Schnittger, 2012 .

Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias

A. Kohlmann, T. Haferlach, S. Schnittger, 2006, Cancer.

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients

A. Kohlmann, C. Corcoran, G. Schiavon, 2017, PloS one.

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

L. Staudt, A. Rosenwald, W. Chan, 2013, Blood.

A novel hierarchical prognostic model of AML solely based on molecular mutations.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Blood.

Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia

Marcos González, J. Hernández-Rivas, A. Kohlmann, 2017, Journal of Hematology & Oncology.

Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Genes, chromosomes & cancer.

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase

Torsten Haferlach, Giuseppe Basso, Robin Foà, 2008, British journal of haematology.

Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2014, Genes, chromosomes & cancer.

Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study.

A. Kohlmann, T. Haferlach, Wei-min Liu, 2008, Clinical chemistry.

New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures

Giuseppe Basso, Alexander Kohlmann, A. Kohlmann, 2006, BMC Genomics.

Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways

L. Bullinger, K. Döhner, H. Döhner, 2010, Leukemia.

Postallogeneic monitoring with molecular markers detected by pretransplant next‐generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms

A. Kohlmann, T. Haferlach, N. Kröger, 2014, European journal of haematology.

Microarray analysis and expression profiling

A. Kohlmann, T. Haferlach, S. Schnittger, 2004 .

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

A. Kohlmann, T. Haferlach, M. Baccarani, 2015, Journal of Cancer Research and Clinical Oncology.

New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes

W. Hiddemann, A. Kohlmann, T. Haferlach, 2005, Leukemia.

Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

Torsten Haferlach, Wolfgang Kern, Wolfgang Hiddemann, 2005, Genes, chromosomes & cancer.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detailed analysis of FLT3 expression levels in acute myeloid leukemia.

W. Hiddemann, A. Kohlmann, T. Haferlach, 2005, Haematologica.

Molecular analyses of 15 , 542 patients with suspected BCR-ABL 1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow by

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Comprehensive mutational profiling in advanced systemic mastocytosis.

A. Kohlmann, T. Haferlach, W. Hofmann, 2013, Blood.

Quantitative comparison of microarray experiments with published leukemia related gene expression signatures

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2009, BMC Bioinformatics.

Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome

A. Kohlmann, T. Haferlach, S. Schnittger, 2013 .

Gene Expression Profiling in AML and MDS Identifies Genes Located on 5q Which Are Consistently Lower Expressed in Cases with 5q Deletion as Compared to Cases with Normal Karyotype.

W. Hiddemann, A. Kohlmann, T. Haferlach, 2004 .

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

N. Schmitz, N. Klopp, T. Illig, 2013, Leukemia.

Gene expression profiling for the diagnosis of acute leukaemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2006, British Journal of Cancer.

Gene Expression Profiling by Microarrays: Gene expression profiling for the diagnosis of acute leukemias

A. Kohlmann, T. Haferlach, S. Schnittger, 2006 .

Pattern robustness of diagnostic gene expression signatures in leukemia

F. Weninger, A. Kohlmann, T. Haferlach, 2005, Genes, chromosomes & cancer.

Gene Expression Profiling as a Diagnostic Tool in Acute Myeloid Leukemia

W. Hiddemann, A. Kohlmann, T. Haferlach, 2004, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics

A. Kohlmann, T. Haferlach, S. Schnittger, 2013 .

Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.

L. Staudt, A. Rosenwald, J. Powell, 2007 .

The role of the RAS pathway in iAMP21-ALL

A. Kohlmann, T. Haferlach, B. Keavney, 2016, Leukemia.

AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features

A. Kohlmann, T. Haferlach, S. Schnittger, 2009, Leukemia.

Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

A. Kohlmann, C. Gedye, C. Corcoran, 2019, Annals of Oncology.

Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups

A. Kohlmann, T. Haferlach, S. Schnittger, 2006, Genes, chromosomes & cancer.

Gene expression analyses in acute myeloid leukaemia (AML): current status and perspectives

A. Kohlmann, T. Haferlach, S. Schnittger, 2008 .

Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN

A. Kohlmann, T. Haferlach, S. Schnittger, 2016, Leukemia.

Role of gene expression profiling for diagnosing acute leukemias.

A. Kohlmann, T. Haferlach, S. Schnittger, 2005, Reviews in clinical and experimental hematology.

Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Blood.

Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival

A. Kohlmann, F. Ciceri, E. Angelucci, 2016, Haematologica.

Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Genes, chromosomes & cancer.

MDS and AML Are Closely Related Diseases: Gene Expression Patterns Reveal Clear Similarities with Respect to Karyotypes and Are Less Related to the Bone Marrow Blast Percentages.

W. Hiddemann, A. Kohlmann, T. Haferlach, 2004 .

Correlation of protein expression and gene expression in acute leukemia

W. Hiddemann, A. Kohlmann, T. Haferlach, 2003, Cytometry. Part B, Clinical cytometry.

Gene expression profiling in acute myeloid leukaemia (AML).

A. Kohlmann, T. Haferlach, C. Haferlach, 2009, Best practice & research. Clinical haematology.

A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia

F. Bosch, P. Abrisqueta, I. Marugán, 2015, PloS one.

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

A. Kohlmann, T. Haferlach, S. Schnittger, 2015, Haematologica.

Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2010 .

ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome

A. Kohlmann, T. Haferlach, S. Schnittger, 2011 .

Post-Allogeneic Monitoring with Molecular Markers Detected by Pre-Transplant Next Generation Sequencing (NGS) Predicts Clinical Relapse in Patients with Chronic Myelomonocytic Leukemia (CMML)

A. Kohlmann, T. Haferlach, N. Kröger, 2012 .

New insights into the biology of acute myeloid leukemia and their impact on treatment.

W. Hiddemann, S. Bohlander, A. Kohlmann, 2003, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

R453Plus1Toolbox: an R/Bioconductor package for analyzing Roche 454 Sequencing data

Martin Dugas, Hans-Ulrich Klein, Christoph Bartenhagen, 2011, Bioinform..

A Generic Concept for Large-scale Microarray Analysis Dedicated to Medical Diagnostics

M Dugas, F Weninger, S Merk, 2006, Methods of Information in Medicine.

A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next‐generation sequencing can be revealed by comparative bioinformatic analyses

S. Ogawa, A. Kohlmann, T. Haferlach, 2014, British journal of haematology.

Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

A. Kohlmann, C. Gedye, C. Corcoran, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA.

Thomas Ernst, Alexander Kohlmann, Andreas Hochhaus, 2013, Clinical chemistry.

Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Leukemia.

Global approach to the diagnosis of leukemia using gene expression profiling.

W. Hiddemann, A. Kohlmann, T. Haferlach, 2005, Blood.

SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.

F. Saad, A. Kohlmann, J. Bono, 2020 .

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA

A. Kohlmann, S. Ramalingam, J. Vansteenkiste, 2020, Journal of Thoracic Oncology.

PQN and DQN: algorithms for expression microarrays.

Jing Wang, Alexander Kohlmann, A. Kohlmann, 2006, Journal of theoretical biology.

A global approach to the diagnosis of leukemia using gene expression profiling

A. Kohlmann, T. Haferlach, W. Kern, 2005 .

Microarray-Genexpressionsanalysen in der Leukämiediagnostik

A. Kohlmann, T. Haferlach, S. Schnittger, 2006, Medizinische Klinik.

Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2011, The Journal of molecular diagnostics : JMD.

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies

A. Kohlmann, T. Haferlach, S. Schnittger, 2010, Annals of Hematology.

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

S. Ogawa, A. Kohlmann, T. Haferlach, 2010, Blood.

The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Genes, chromosomes & cancer.

Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies.

A. Kohlmann, T. Haferlach, U. Bacher, 2009, Briefings in functional genomics & proteomics.

A global approach to the diagnosis of leukemia using gene expression profiling

A. Kohlmann, T. Haferlach, W. Kern, 2005 .

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Haematologica.

Gene Expression Profiling to Detect New Treatment Targets in Leukemia and Lymphoma: A Future Perspective

A. Kohlmann, T. Haferlach, W. Kern, 2019, Innovative Leukemia and Lymphoma Therapy.

Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study

A. Kohlmann, T. Haferlach, T. Lion, 2013 .

AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions.

A. Kohlmann, T. Haferlach, S. Schnittger, 2009 .

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS .

A. Kohlmann, T. Haferlach, S. Schnittger, 2009 .